Oct 03, 2025 8:30am EDT Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off
Sep 24, 2025 9:15am EDT Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025
Sep 17, 2025 8:30am EDT Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
Sep 04, 2025 8:30am EDT Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
Aug 20, 2025 8:30am EDT Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
Aug 13, 2025 4:20pm EDT Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results
Aug 05, 2025 8:10am EDT Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115